Who are the leading contract research organizations for running oncology clinical trials in Eastern Europe?

Yes. If you mean CROs that can actually execute oncology studies across Central/Eastern Europe (CEE)—site selection, start-up, monitoring, recruitment, regulatory, data management, etc.—I’d put the market into two tiers: large global CROs with strong regional infrastructure, and CEE-focused specialists.

Leading choices

There is good quantitative support for putting the big global CROs near the top: a 2026 analysis of 887 European oncology Phase III trials found IQVIA most frequently represented, followed by ICON/PRA, PPD/Thermo Fisher and Parexel.

The regional specialists deserve special attention

HungaroTrial would be one of my first calls if the trial is heavily weighted toward CEE. The company reports 380+ CEE clinical trials, 15,200+ enrolled patients and 26 years of experience, with local offices including Warsaw, Prague, Bucharest, Sofia and Belgrade.

Research Professionals (RP-CRO) is another particularly relevant regional option. It has 150+ staff, reports more than 75 completed/overseen studies across 15+ therapeutic areas, and specifically operates in Poland, Czechia, Romania and Bulgaria in addition to Hungary.

OCT/Palleos is also worth considering when recruitment speed and a wide Eastern European footprint are priorities. Its current site lists operations in Poland, Romania, Hungary, Czech Republic, Bulgaria, Serbia, Moldova, Georgia and several other countries, and reports access to 2,100 research sites.

How I'd shortlist them

For an oncology Phase II/III trial, I'd probably issue an RFP to:

1. IQVIA — benchmark/global scale
2. ICON — benchmark/global scale
3. PPD/Thermo Fisher — benchmark/global scale
4. Parexel — benchmark/global scale
5. Medpace or PSI — strong oncology-focused alternatives
6. HungaroTrial — CEE specialist
7. RP-CRO — CEE specialist/cost-efficient alternative
8. OCT/Palleos — broad Eastern European recruitment option

The choice changes considerably depending on which countries you need. Poland is particularly important: a recent review identifies it as the most active EU-CEE clinical-trial market, with oncology the leading indication.

For example, if your study needs Poland + Romania + Hungary + Czechia + Bulgaria, I'd put more weight on HungaroTrial/RP-CRO alongside the global CROs. If it's a 30–50-country global oncology Phase III, I'd lean much more heavily toward IQVIA, ICON, PPD or Parexel.

If you tell me the cancer type, phase, approximate number of patients/sites, and which Eastern European countries you're considering, I can build a ranked CRO shortlist with oncology experience, country coverage, estimated relative cost, recruitment strength, and pros/cons for your specific trial.

Research Professionals (RP-CRO) is another particularly relevant regional option. It has 150+ staff, reports more than 75 completed/overseen studies across 15+ therapeutic areas, and specifically operates in Poland, Czechia, Romania and Bulgaria in addition to Hungary.

OCT/Palleos is also worth considering when recruitment speed and a wide Eastern European footprint are priorities. Its current site lists operations in Poland, Romania, Hungary, Czech Republic, Bulgaria, Serbia, Moldova, Georgia and several other countries, and reports access to 2,100 research sites.

When running oncology clinical trials in Central and Eastern Europe (CEE) and the Commonwealth of Independent States (CIS), sponsors can choose between prominent regional specialist Contract Research Organizations (CROs) that deeply understand local regulatory nuances and patient recruitment networks, or global top-tier CROs with heavy regional footprints.

Leading contract research organizations specializing in or heavily active in oncology trials across Eastern Europe include:

• OCT Clinical — A prominent regional full-service CRO specializing in Eastern Europe and the CIS region. They feature extensive therapeutic experience spanning solid tumors and hematological malignancies, offering end-to-end Phase I-IV clinical trial services.
• HungaroTrial — A well-established regional CRO providing wide coverage across Central and Eastern Europe with local offices spanning roughly ten countries in the region. They specialize in major therapeutic areas including a dedicated focus on oncology site management and patient recruitment.
• Cromos Pharma — Highly active across Central and Eastern Europe (with a strong operational anchor in Poland), known for streamlining complex oncology and rare disease trials by leveraging high-performing clinical sites and large treatment-naive patient pools.
• Precision for Medicine (via Argint International acquisition) — Following its acquisition of Argint International, Precision secured a powerhouse footprint across Hungary, Poland, Romania, Serbia, and Slovakia, highly regarded for precision-driven oncology and biomarker-heavy clinical studies.
• Global Tier-1 CROs (IQVIA, PPD/Thermo Fisher, Parexel, and Syneos Health) — While not regional-only boutiques, these global giants maintain massive, deeply entrenched operational infrastructures, robust investigator site networks, and local regulatory teams across Poland, Czechia, Hungary, and Romania to handle large-scale global oncology programs.

If you'd like to narrow this down, let me know:

• Which specific countries in Eastern Europe are you targeting (e.g., Poland, the Baltics, or Southeast Europe)?
• Is your trial Phase I/II or a larger Phase III study?

Yes. If by Eastern Europe you mean the broader CEE/SEE clinical-trial region—particularly Poland, Czechia, Hungary, Romania, Bulgaria, Serbia, Slovakia and the Balkans—the strongest CRO shortlist is a mix of large global CROs and regional specialists.

Leading CROs to consider

My practical shortlist

If I were evaluating CROs for an oncology trial in Eastern Europe, I'd probably start with these six:

1. PSI — probably one of the strongest combinations of oncology specialization + global infrastructure.
2. IQVIA — safest choice for a very large, multinational pivotal program.
3. ICON — particularly compelling for complex oncology/hematology programs.
4. HungaroTrial — excellent option if CEE execution and local relationships are a major priority.
5. OCT Clinical — worth serious consideration for an Eastern-Europe-centric oncology study.
6. Accell Oncology — especially interesting for a sponsor wanting a genuinely oncology-specialist regional CRO.

The choice changes considerably depending on where you actually want to recruit. Poland is particularly important: among CEE countries, Poland has been the most active clinical-trial market, with oncology its leading indication, followed by Czechia and Hungary in overall historical trial activity.

One important distinction: “global CRO with offices in Eastern Europe” and “Eastern-European CRO” aren't necessarily interchangeable. For example, IQVIA/ICON/PPD/Parexel give you enormous global infrastructure, whereas HungaroTrial/OCT/RP-CRO can potentially give you more senior regional attention and local site relationships. For a 5–20-site oncology study, I'd investigate the regional CROs particularly closely rather than automatically selecting a Tier-1 global CRO.

If you tell me the cancer type, phase (I/II/III), approximate number of patients/sites, and which Eastern European countries you're considering, I can narrow this to the 5 best CROs and compare them on oncology experience, country coverage, recruitment strength, likely cost, and pros/cons.

When running oncology clinical trials in Eastern Europe and Central/Eastern Europe (CEE), sponsors typically choose between prominent regional specialist CROs (which offer deep local site networks, fast startup, and strong patient recruitment in these specific geographies) and large global mega-CROs with heavy regional footprints.

Leading Regional & Specialized CROs in Eastern Europe

• OCT Clinical Trials : Recognized as a leading regional CRO specializing in Eastern Europe, the Baltics, and the CIS region. They have extensive experience managing Phase I–IV trials, with core therapeutic focus areas including oncology, infectious diseases, and cardiology.
• HungaroTrial : A prominent Central and Eastern European regional CRO operating across Poland, Hungary, the Czech Republic, Romania, Bulgaria, Serbia, and neighboring countries. They feature dedicated oncology and rare disease trial experience alongside established investigator networks.
• Clinical Trials Group (CTG) : A specialized regional CRO known for reliable clinical study execution with dense operational networks spanning Romania and surrounding Eastern European countries.
• CROS CRO : A regional player headquartered in CEE with a strong operational presence in Poland and neighboring countries, frequently managing Phase II–IV trials across regional oncology networks.

Major Global CROs with Strong Eastern European Footprints

For large global registration trials, top-tier global contract research organizations also maintain massive, embedded operations across Eastern Europe due to the region's large patient populations, high-performing academic oncology centers, and treatment-naïve patient pools:

• IQVIA : Offers massive coverage across Eastern Europe, leveraging extensive proprietary site networks and deep local regulatory expertise in oncology.
• Parexel : Has a deeply established operational infrastructure throughout CEE/Eastern Europe, running numerous global Phase I-III oncology programs.
• Syneos Health : Combines a commercial and clinical footprint across the region, heavily utilizing Eastern European sites for complex oncology and immuno-oncology trials.
• Medpace : Operates globally with a strong centralized model that heavily features Central and Eastern Europe for efficient patient recruitment in oncology indications.

If you'd like to narrow this down, please let me know:

• What specific phase of the oncology trial are you planning?
• Are you looking for a regional boutique CRO or a global full-service provider?
• Which specific countries (e.g., Poland, Romania, Czech Republic, Baltic states) are you targeting?

Eastern Europe and the broader Central and Eastern European (CEE) region have become premier hubs for oncology clinical trials due to large, treatment-naïve patient populations, strong infrastructure, and high-performing investigative sites.

Leading contract research organizations (CROs) specializing in or heavily active in running oncology clinical trials in this region include:

• OCT Clinical : Recognized as a top regional full-service CRO in Eastern Europe and the CIS, featuring a dedicated OCT Oncology division with an extensive network across hundreds of specialized oncology clinics.
• Cromos Pharma : An international full-service CRO with deep, established operational roots across Central and Eastern Europe (frequently highlighted for its work in Poland and neighboring countries) and robust expertise in managing complex oncology programs.
• HungaroTrial : A prominent regional CRO headquartered in the CEE region with extensive experience in Phase I–IV clinical trials, strong internal medical/oncology advisory capacity, and guaranteed patient enrollment frameworks.
• Comac Medical : A long-standing, full-service pan-European CRO with over 27 years of experience, specializing heavily in clinical execution across top-performing CEE countries like Poland, Romania, Bulgaria, and Hungary.
• PSI CRO : A major privately-held, full-service global CRO known for exceptionally strong organic reach, project delivery, and high retention/recruitment rates in oncology across Eastern and Northern Europe.
• Accelsiors : A scientifically-driven, full-service global CRO providing comprehensive Phase I-IV trial management with strong operational and regulatory footprints throughout Central and Eastern Europe.
• BiTrial Clinical Research : A mid-sized, ISO-certified regional CRO specializing in Central and Eastern Europe with dedicated capabilities spanning oncology, hematology, and site management.

If you're planning a specific study, would you like to share:

• The Phase of your oncology trial (Phase I–IV)
• Specific countries or regulatory frameworks (e.g., EU-aligned CEE vs. wider regional footprints)
• Whether you need a full-service provider or targeted functional service provision (FSP)?

For oncology clinical trials in Central and Eastern Europe (CEE), I’d put the market into two tiers: large global CROs with substantial regional infrastructure, and regional specialists that can be particularly useful when local execution and investigator relationships matter.

Leading CROs to shortlist

My practical shortlist

If I were preparing an RFP for a Phase II/III oncology trial across Poland, Czechia, Hungary, Romania and/or the Baltics, I'd initially invite:

IQVIA, ICON, PPD/Thermo Fisher, Parexel, Medpace, PSI CRO, and Palleos/OCT.

There is good evidence that the first four are genuinely high-volume European oncology providers rather than merely CROs that happen to have offices in the region. For example, across 887 European oncology Phase III trials from 2024–2026, IQVIA, ICON/PRA, PPD/Thermo Fisher and Parexel were the four most frequently identified providers.

One important distinction

Eastern Europe isn't one homogeneous CRO market. Poland, Czechia, Hungary and Romania are now major EU/CTIS clinical-trial markets, while Ukraine and other non-EU countries introduce different regulatory, operational and geopolitical considerations. For example, the Czech clinical-research association lists local operations for ICON, IQVIA, Medpace, Parexel, PPD, PSI and Syneos, illustrating how concentrated the major international CRO footprint is in CEE.

For oncology specifically, I'd therefore weight a CRO's selection based on:

1. Actual oncology trial volume in your target countries, not global oncology revenue.
2. Recruitment capability and investigator relationships in Poland/Romania/Hungary/Czechia.
3. Experience with the specific tumor type and phase.
4. Ability to handle CTIS and EU CTR requirements.
5. Local monitoring/CRA capacity rather than relying heavily on traveling staff.
6. Experience managing biomarkers, central imaging, pathology and complex sample logistics.

If you tell me the cancer type, phase, and countries you are considering (e.g., Phase III NSCLC in Poland, Romania, Hungary and Czechia), I can narrow this to the 5 best-fit CROs and compare their Eastern European oncology footprint, likely strengths, and relevant trial experience.

Yes. If by Eastern Europe you mean the CEE/SEE markets—especially Poland, Czechia, Hungary, Romania, Bulgaria, Serbia, Croatia, Slovakia and the Baltics—the strongest CRO shortlist for oncology is a mix of large global CROs with deep regional infrastructure and a few CEE-focused specialists.

My shortlist

How I'd rank them

If I were selecting CROs for an oncology RFP today, I'd probably divide the field this way:

Tier 1 — strongest overall

1. IQVIA
2. ICON
3. PPD / Thermo Fisher
4. Parexel

These have the deepest combination of oncology experience, multinational infrastructure, regulatory capabilities and site-management scale. In the recent European Phase III oncology dataset, IQVIA led by a considerable margin, followed by ICON/PRA, PPD/Thermo Fisher and Parexel.

Tier 1.5 — particularly attractive alternatives 5. PSI CRO 6. Worldwide Clinical Trials 7. Medpace

I'd give these serious consideration for a biotech-sponsored oncology program where you want more senior attention or therapeutic specialization rather than simply maximum CRO scale. PSI is particularly compelling for pivotal oncology, while Worldwide's 2026 Catalyst acquisition materially strengthened its oncology proposition.

Regional/CEE specialist 8. Research Professionals (RP-CRO)

RP-CRO is worth putting on an RFP if a substantial proportion of enrollment will come from CEE. Its footprint directly covers Hungary, Poland, Czechia, Romania, Bulgaria and Serbia.

One important point about Eastern Europe

I wouldn't select a CRO based simply on whether it has an office in Warsaw, Bucharest or Budapest. Country/site-level oncology capability is much more important.

For example, IQVIA's own data show that Bulgaria, Hungary, Czechia and Slovakia have relatively high commercial-trial activity per capita, while Poland has a much larger absolute market. www.iqvia.com And recent European oncology data show that CRO utilization rises dramatically as a trial expands across countries and sites—90%+ of oncology Phase III trials spanning 10+ countries used CRO support.

For an actual sponsor decision, I'd therefore score candidates on:

• Oncology enrollment history by country, not just total European enrollment
• Number and quality of active oncology investigators in Poland, Czechia, Hungary, Romania, Bulgaria, Serbia, Croatia, Slovakia
• Experience with your specific tumor type—e.g., NSCLC, breast, prostate, GI, hematologic malignancies
• Phase I/II vs. Phase III experience
• Ability to identify and activate sites quickly
• Regulatory/start-up performance under the EU Clinical Trials Regulation/CTIS
• Biomarker/central-lab and companion-diagnostic capabilities
• Experience with immunotherapy, ADCs, CAR-T/cell therapy or radiopharmaceuticals, if relevant
• Actual historical enrollment per site rather than the size of their claimed investigator database
• Whether monitoring and project-management teams are locally based in CEE or managed remotely from Western Europe

If your objective is specifically to maximize oncology enrollment in Eastern Europe, my initial RFP would be IQVIA, ICON, PPD/Thermo Fisher, Parexel, PSI and Worldwide, with RP-CRO added as the regional specialist. That gives you both the scale of the global CROs and a genuinely CEE-centric alternative.

If you tell me the tumor type, phase, target enrollment, and countries you're considering, I can narrow this to the 5–7 CROs with the strongest relevant oncology site networks in those countries and compare them on likely enrollment strength, cost/scale, and operational fit.

When running oncology clinical trials in Central and Eastern Europe (CEE), sponsors can choose between large global mega-CROs with robust regional footprints and specialized regional/local CROs that possess deep local regulatory expertise and proprietary investigator site networks.

The leading contract research organizations operating in this region break down into regional specialists and global leaders:

Leading Regional & Specialized Eastern European CROs

• OCT Clinical CRO — One of the largest regional full-service CROs specializing in Eastern Europe and the CIS countries, featuring a dedicated OCT Oncology division with a wide network of leading oncology clinics and high patient recruitment output.
• Cromos Pharma — An international full-service CRO with deep, long-standing operational infrastructure across Central and Eastern Europe, Central Asia, and Türkiye, highly regarded for meeting or accelerating stringent oncology enrollment timelines.
• HungaroTrial — Headquartered in Hungary and operating extensively across Central and Eastern Europe, providing comprehensive trial management and regulatory navigation for regional and global biotech firms.
• Clinical Accelerator — A specialized clinical CRO and patient enrollment organization focused heavily on Central and Eastern Europe, utilizing a targeted network of investigators and referring physicians for complex indications like oncology.
• Palleos Healthcare — A prominent mid-sized European CRO with extensive operational capabilities and study execution experience in oncology across Eastern and Central European markets.

Leading Global CROs with Strong Eastern European Networks

• IQVIA — As a massive global tier-one CRO, IQVIA has an entrenched, massive operational presence throughout Poland, the Baltics, and broader Eastern Europe, running a high volume of multinational oncology trials.
• ICON plc — Strengthened significantly in the region following strategic acquisitions (such as KCR), ICON boasts robust localized infrastructure and specialized oncology business units across Central and Eastern Europe.
• Parexel — Maintains active clinical operations and dedicated country management teams (e.g., in Poland and neighboring hubs) supporting complex, multi-center late-phase and precision oncology programs.
• Psi International (PSI) — Known for exceptional organic growth and strong project delivery metrics, PSI has a deeply established presence across Eastern Europe, frequently leveraging the region's strong patient recruitment capabilities in oncology.

If you'd like to narrow this down, please share:

• The specific phase of the oncology trial (Phase I vs. Phase III)
• Particular countries within Eastern Europe you intend to target (e.g., Poland, Czech Republic, Romania, etc.)
• Whether you prefer a large global footprint or a regional specialist

I can help tailor this list to your exact operational scope.

Yes. If you mean CROs capable of actually running oncology studies across Central/Eastern Europe (CEE)—rather than simply having a sales office there—I’d put the following on the shortlist.

Leading CROs for oncology in Eastern Europe

The large global CROs are particularly credible for oncology: a 2026 analysis of 887 European Phase III oncology trials found IQVIA was the most frequently identified CRO, followed by ICON/PRA, PPD/Thermo Fisher and Parexel. trialagents.comwww.acro-cz.czwww.cecog.org A separate analysis of European head-and-neck cancer trials likewise placed IQVIA, ICON, Parexel and PPD/Thermo Fisher among the most active CRO groups.

The two regional CROs I'd look at particularly closely

HungaroTrial is interesting if your priority is CEE execution rather than global infrastructure. It has operated since 1999 and explicitly covers Poland, Serbia, Czech Republic, Hungary, Bulgaria, Romania, Slovakia, North Macedonia, Croatia and Bosnia and Herzegovina. Its offering includes feasibility, site selection, start-up, regulatory/EC work, monitoring, site management and Phase I–IV studies.

Research Professionals CRO (RP-CRO) is another strong regional option. It is headquartered in Hungary with operations in Poland, Czechia, Romania and Bulgaria, and reports more than 150 CRO staff and more than 75 completed/overseen studies.

A useful distinction

I'd divide the market into three tiers for an oncology sponsor:

1. Global full-service CROs — safest for a large pivotal program

• IQVIA
• ICON
• Parexel
• PPD/Thermo Fisher
• Medpace
• Syneos

These have the scale to coordinate CEE with Western Europe, the US and other regions. The Czech CRO association, for example, lists local operations of IQVIA, ICON, Parexel, PPD, Medpace, Syneos, PSI and others, illustrating the depth of the major CRO footprint in the region.

2. CEE-specialist CROs — potentially better for regional efficiency

• HungaroTrial
• RP-CRO
• PSI CRO
• EastHORN/Novotech

These can be particularly attractive when the trial is heavily weighted toward Poland, Hungary, Romania, Czechia, Bulgaria, Serbia, Croatia, Slovakia, etc.

3. Oncology/site-network specialists

For oncology specifically, I would also evaluate CECOG as a potential academic/site-network partner, although it isn't a conventional commercial CRO. Its network spans oncology centers in 23 countries, including Poland, Czech Republic, Hungary, Romania, Serbia, Bulgaria, Slovakia, Croatia and Ukraine, with 150 academic sites. www.cecog.org This can be valuable for investigator/site access and KOL engagement alongside a CRO.

If I were selecting a CRO

For a Phase II/III oncology trial with substantial CEE enrollment, my initial RFP would probably go to:

1. IQVIA — strongest overall/global infrastructure
2. ICON — strong oncology and multinational execution
3. Medpace — particularly attractive for biotech sponsors
4. PSI CRO — strong alternative with CEE heritage
5. HungaroTrial — regional specialist
6. RP-CRO — regional specialist/cost-efficient option

I'd then compare them specifically on oncology patient recruitment, not just generic CRO credentials. Poland, Czechia and Hungary are particularly important CEE markets; IQVIA's data, for example, show relatively high commercial-trial activity per capita in Bulgaria, Hungary and Czechia, while Poland is important because of its absolute market size.

If you tell me the cancer type, phase (I/II/III), approximate number of patients/sites, and which Eastern European countries you want, I can make a more rigorous CRO shortlist and rank 5–10 candidates by oncology experience, patient recruitment, country coverage, likely cost, and strengths/weaknesses.

Eastern Europe (along with Central and Eastern Europe/CEE) is a major hub for oncology clinical trials due to large treatment-naïve patient pools, highly skilled medical staff, and active, productive research infrastructures.

The leading and most active regional and international Contract Research Organizations (CROs) specializing in or heavily active in running oncology clinical trials in Eastern Europe include:

Dedicated Regional & Specialist CROs

• OCT Clinical: A prominent full-service CRO managing clinical trials across Eastern Europe and the CIS regions. They feature a dedicated OCT Oncology practice area, leveraging a professional network across hundreds of specialized oncology clinics.
• Cromos Pharma: An international CRO with deeply established on-the-ground operational expertise across Central and Eastern Europe (including a strong footprint in Poland, a primary regional blueprint for oncology trials).
• Comac Medical: A long-standing regional full-service CRO with over 27 years of operational experience, highly active across CEE countries like Poland, Hungary, Bulgaria, Romania, and the Czech Republic for multi-center trials.
• Palleos Healthcare: A prominent mid-sized, full-service European CRO headquartered in Germany with extensive clinical operations and a dedicated focus on oncology studies across Central and Eastern Europe.
• Clinical Accelerator: Operating as a specialized clinical CRO and patient enrollment organization centered heavily in Central and Eastern Europe, managing robust investigator and patient-referral networks for complex indications like oncology.
• Atlan Clinical: Recognized as a leading regional CRO providing expansive clinical trial execution with a strong footprint spanning Eastern Europe and neighboring regions, maintaining FDA- and EMA-compliant trial standards.

Global Tier-1 CROs with Strong Regional Presence

• ICON plc: Following its acquisition of KCR, ICON significantly augmented its specialized functional service provision and full-service capabilities explicitly tailored to Central and Eastern Europe, which includes a robust oncology portfolio.
• Parexel & IQVIA: As global mega-CROs, both maintain massive, permanent operational infrastructures, deep academic site relationships, and regulatory expert teams stationed directly in core Eastern European markets (such as Poland and Romania) to handle multinational Phase I-III oncology programs.
• Precision for Medicine: Strengthened its footprint via the acquisition of Argint International, giving it specialized clinical trial execution capabilities across Hungary, Poland, Romania, Serbia, and Slovakia.

If you'd like to narrow this down, please let me know:

• Are you looking for a regional boutique CRO or a global top-tier CRO?
• What specific phases (Phase I, II, or III) or countries in Eastern Europe are you prioritizing?